Bank of New York Mellon’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $20.6M | Buy |
800,283
+32,244
| +4% | +$663K | ﹤0.01% | 1607 |
|
|
2026
Q1 | $14.7M | Buy |
768,039
+5,952
| +0.8% | +$118K | ﹤0.01% | 1706 |
|
|
2025
Q4 | $12.6M | Sell |
762,087
-38,660
| -5% | -$653K | ﹤0.01% | 1797 |
|
|
2025
Q3 | $11.6M | Buy |
800,747
+9,991
| +1% | +$144K | ﹤0.01% | 1850 |
|
|
2025
Q2 | $11.1M | Sell |
790,756
-313,136
| -28% | -$4.41M | ﹤0.01% | 1843 |
|
|
2025
Q1 | $15M | Sell |
1,103,892
-139,095
| -11% | -$2.67M | ﹤0.01% | 1644 |
|
|
2024
Q4 | $25.3M | Sell |
1,242,987
-87,364
| -7% | -$2.24M | ﹤0.01% | 1429 |
|
|
2024
Q3 | $38.8M | Sell |
1,330,351
-209,920
| -14% | -$5.2M | 0.01% | 1193 |
|
|
2024
Q2 | $35.8M | Sell |
1,540,271
-237,636
| -13% | -$4.56M | 0.01% | 1226 |
|
|
2024
Q1 | $36.5M | Sell |
1,777,907
-92,720
| -5% | -$1.74M | 0.01% | 1231 |
|
|
2023
Q4 | $40.1M | Sell |
1,870,627
-93,061
| -5% | -$1.84M | 0.01% | 1198 |
|
|
2023
Q3 | $40.5M | Sell |
1,963,688
-26,019
| -1% | -$660K | 0.01% | 1130 |
|
|
2023
Q2 | $58.7M | Sell |
1,989,707
-26,916
| -1% | -$757K | 0.01% | 917 |
|
|
2023
Q1 | $46.5M | Buy |
2,016,623
+10,703
| +0.5% | +$295K | 0.01% | 1053 |
|
|
2022
Q4 | $55.8M | Buy |
2,005,920
+110,628
| +6% | +$3.29M | 0.01% | 915 |
|
|
2022
Q3 | $58.2M | Buy |
1,895,292
+27,162
| +1% | +$883K | 0.01% | 866 |
|
|
2022
Q2 | $55M | Buy |
1,868,130
+258,913
| +16% | +$6.78M | 0.01% | 922 |
|
|
2022
Q1 | $51.8M | Buy |
1,609,217
+676,625
| +73% | +$23.3M | 0.01% | 1070 |
|
|
2021
Q4 | $41.6M | Buy |
932,592
+555,873
| +148% | +$26.3M | 0.01% | 1282 |
|
|
2021
Q3 | $19M | Buy |
376,719
+29,350
| +8% | +$1.65M | ﹤0.01% | 1750 |
|
|
2021
Q2 | $27.2M | Buy |
347,369
+86,005
| +33% | +$5.32M | 0.01% | 1560 |
|
|
2021
Q1 | $14.9M | Sell |
261,364
-178,006
| -41% | -$11.9M | ﹤0.01% | 1872 |
|
|
2020
Q4 | $36.8M | Sell |
439,370
-288,839
| -40% | -$17.5M | 0.01% | 1247 |
|
|
2020
Q3 | $26.1M | Buy |
728,209
+82,247
| +13% | +$2.48M | 0.01% | 1298 |
|
|
2020
Q2 | $15.6M | Buy |
645,962
+302,215
| +88% | +$7.11M | ﹤0.01% | 1590 |
|
|
2020
Q1 | $6.02M | Buy |
343,747
+7,517
| +2% | +$157K | ﹤0.01% | 1983 |
|
|
2019
Q4 | $5.86M | Sell |
336,230
-2,687
| -0.8% | -$44.7K | ﹤0.01% | 2254 |
|
|
2019
Q3 | $5.19M | Buy |
338,917
+111,897
| +49% | +$2.14M | ﹤0.01% | 2263 |
|
|
2019
Q2 | $4.71M | Sell |
227,020
-1,154
| -0.5% | -$25.9K | ﹤0.01% | 2360 |
|
|
2019
Q1 | $5.3M | Buy |
228,174
+669
| +0.3% | +$14K | ﹤0.01% | 2308 |
|
|
2018
Q4 | $4.7M | Buy |
227,505
+23,809
| +12% | +$432K | ﹤0.01% | 2336 |
|
|
2018
Q3 | $4.43M | Buy |
203,696
+142,500
| +233% | +$2.36M | ﹤0.01% | 2464 |
|
|
2018
Q2 | $933K | Buy |
61,196
+8,882
| +17% | +$167K | ﹤0.01% | 3283 |
|
|
2018
Q1 | $1.03M | Buy |
+52,314
| New | +$1.08M | ﹤0.01% | 3200 |
|
Other funds holding DNLI
N
Bank of New York Mellon's DNLI Position: Q2 2026 in Review
Bank of New York Mellon increased its Denali Therapeutics (DNLI) stake by 4.2% in Q2 2026, buying an estimated $663K and bringing the position to 800,283 shares worth $20.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1607.
Bank of New York Mellon first reported a position in DNLI in Q1 2018 and has held it in 34 quarters since. The position peaked at $58.7M in Q2 2023. 128 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.
- Bank of New York Mellon held 800,283 shares of Denali Therapeutics worth $20.6M as of Q2 2026.
- Bank of New York Mellon bought 32,244 Denali Therapeutics shares in Q2 2026, an estimated $663K.
- Denali Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #1607 holding.
- Bank of New York Mellon first reported a position in Denali Therapeutics in Q1 2018 and has held it in 34 quarters since.
- Bank of New York Mellon's Denali Therapeutics position peaked at $58.7M in Q2 2023.
- 128 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.